Insider buying last 90 days
No open-market insider purchases were filed for OMCL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every OMCL insider filing, plotted on the chart in Gekko.Open OMCL in Gekko
NASDAQ: OMCL
Omnicell (OMCL) Stock Analysis & Forecast
Oct 12 close
$36.87+1.05 (+2.9%)
Gekko Brief
AI summaryOct 12 closeThis week's coverage centers on Omnicell's recent quarterly report and the reaction to its guidance. Commentary notes that revenue came in slightly above expectations, with a 7.4% year-on-year increase, but EBITDA guidance for the next quarter came in weaker than forecast, shifting attention toward cost pressures and future profitability. Separate coverage also compares Omnicell against Baxter International on profitability, risk and valuation measures, while other items confirm that third-quarter 2026 results are scheduled for release.
OMCL closed at $36.87, up 2.9% on the day, with a one-month return of 12.4% but a three-month return of -19.7%. The close sits between its 50-day average of $34.71 and 200-day average of $39.84, reflecting a mixed trend. The GekkoIndex reads 50, placing the stock in the Neutral zone, with a five-day change of -7.1. Gekko Fair Value stands at $38.85, putting the current price 5.1% below that level.
Over the next 20 trading days, the main event is the Q3 FY26 earnings release on 29 October, before the open, 17 days away and inside a typical holding window. The last earnings reaction moved the stock -14.6%, against an average absolute reaction of 14.2% across prior quarters. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality for this calendar stretch has averaged -2.7% over 5 years, rising in 3 of those years, a pattern worth noting ahead of the report.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Omnicell price vs fair value
Close $36.87200-day averageGekko Fair Value $38.85
Omnicell quick facts
- Market cap
- $1.68B
- P/E ratio
- 41.5
- Forward P/E
- 29.5
- EPS, TTM
- $0.84
- Revenue, TTM
- $1.25B
- Profit margin
- 3.1%
- Dividend yield
- —
- Beta
- 0.99
- Volume
- 459,029 avg 511,752
- 1-year return
- +18.5%
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±9.1%
- 50-day average
- $34.71
- 200-day average
- $39.84
- Next earnings
- Oct 29 before open
- Shares outstanding
- 45.61M
Omnicell swing-trade checklist
Omnicell scores 1 supportive, 3 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed1 headwind
- Trendmixed
Averages disagree
Close $36.87 sits between the 50-day ($34.71) and 200-day ($39.84) averages, or the averages disagree.
See the chart - GekkoIndexmixed
50, Neutral
Reading 50 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
5.1% below
Price is 5.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 17 days
Reports on Oct 29, 2026, 17 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−2.7% on average
From this point in the calendar, the next 20 trading days averaged −2.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Omnicell stock chart and price history
Omnicell closed at $36.87 on Oct 12, 2026, +18.5% over the past year, inside a 52-week range of $29.06 to $55.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +12.4%
- 3 months
- −19.7%
- 6 months
- +5.3%
- 1 year
- +18.5%
The full OMCL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open OMCL in Gekko
Follow Omnicell through every session
Put OMCL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track OMCL in GekkoFree for 7 days. No credit card required.
About Omnicell
Omnicell supplies technology used across healthcare settings in the United States and abroad, with equipment and software that support how clinicians handle medications and supplies. Its catalog spans automated dispensing cabinets such as Titan XT, a swap-in console called XTExtend, and dispensing services for both central pharmacies and medication-at-the-bedside workflows. It is also known for IV compounding tools, specialty pharmacy support, and the EnlivenHealth platform built for retail and community pharmacies.
The company's offerings extend into medication adherence packaging, ongoing software and hardware maintenance, on-site servicing and parts, staff training, and program management. A cloud platform called OmniSphere and tools for tracing medicines and supplies through the healthcare system round out its lineup. Its customers are hospitals, health systems, and pharmacies that rely on these systems to manage medication handling.
Omnicell traces back to incorporation in 1992 and operated earlier as Omnicell Technologies before adopting its current name in 2001. It is headquartered in Fort Worth, Texas, and its shares are listed on the NASDAQ under the ticker OMCL.
- Listed
- NASDAQ
- Sector
- Technology services
- Industry
- Information technology services
- Website
- omnicell.com
Omnicell GekkoIndex: the smart money zone
Omnicell’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50, in the Neutral zone, down 7.1 points over five sessions.
50Neutral
Down 7.1 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | +0.4% | −0.7% | ||
| Accumulation | 271 | +0.3% | +1.9% | ||
| Neutral (current zone) | 322 | +0.2% | +0.3% | ||
| Distribution | 33 | +1.0% | +7.0% | ||
| Selling | 4 | Too few readings yet | |||
Average OMCL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the OMCL price, zone by zone.Track OMCL in Gekko
Is Omnicell stock overvalued? Gekko Fair Value
Omnicell trades 5.1% below Gekko Fair Value of $38.85, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Omnicell shares are worth, recalculated every trading day.
$38.85
Gekko Fair Value, Oct 10, 2026
5.1% Undervalued
At the end of Aug 2026 the price was 14.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open OMCL in Gekko
Omnicell insider and Congress trading
No open-market insider purchases were filed for Omnicell, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in OMCL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for OMCL, plotted on the chart in Gekko.Open OMCL in Gekko
Buybacks
Omnicell has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $388K
- As a share of market cap
- 0.02%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold OMCL.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Omnicell earnings: next date and track record
Omnicell reports on Oct 29, 2026, before the open (17 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 17 days away
- EPS estimate
- $0.42
- Revenue estimate
- $304.4M
7 of 8reports beat the EPS estimate
±14.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Omnicell reported Q2 2026 total revenue of $312 million at the high end of guidance, with non-GAAP EBITDA of $67 million and non-GAAP EPS of $0.94 both exceeding expectations. The company appointed Nnamdi Njoku as President and COO to accelerate operational execution. Pipeline activity is increasing for OmniSphere and Titan XT solutions, supported by expanding leasing programs as customers prioritize enterprise-wide medication management platforms.
- Guidance
- Management provided Q3 and full year 2026 outlook with details to be covered by CFO Baird Radford. The company sees 2026 as early stages of a refresh cycle transitioning from XT to Titan XT, suggesting growing revenue opportunity ahead.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.70 est $0.31 | $312.2M est $310.2M | −14.6% |
| Apr 28, 2026 | $0.55 est $0.33 | $309.9M est $304.0M | +14.5% |
| Feb 5, 2026 | $0.40 est $0.47 | $314.0M est $313.4M | −20.6% |
| Oct 30, 2025 | $0.51 est $0.36 | $310.6M est $295.6M | +13.5% |
| Jul 31, 2025 | $0.45 est $0.31 | $290.6M est $292.1M | +0.2% |
| May 6, 2025 | $0.26 est $0.16 | $269.7M est $278.1M | −19.2% |
| Feb 6, 2025 | $0.60 est $0.57 | $306.9M est $297.9M | −9.5% |
| Oct 30, 2024 | $0.56 est $0.41 | $282.4M est $297.9M | +21.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Omnicell stock forecast and analyst price targets
Analysts’ average 12-month price target for Omnicell is $57.86, +56.9% from the last close, from 5 firms rating the stock in the last 90 days.
$57.86consensus 12-month target, +56.9% from the last close
Now $36.87Avg $57.86
Low $45High $65
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 24 | KeyBanc | $65 | +76.3% |
| Aug 3 | Piper Sandler | $45 | +22.1% |
| Jul 31 | Bank of America Securities | — | — |
| Jul 31 | KeyBanc | $65 | +76.3% |
| Jul 30 | Wells Fargo | $50 | +35.6% |
+0.3%average 20-day move after past Neutral readings
−2.7%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Omnicell seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Omnicell averaged −2.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 2 of 5 |
| Next 10 trading days | −3.8% | 2 of 5 |
| Next 15 trading days | +4.7% | 3 of 5 |
| Next 20 trading days | −2.7% | 3 of 5 |
| Next 30 trading days | −5.5% | 2 of 5 |
For scale, OMCL’s typical 20-trading-day move in either direction is about 9.1%.
Omnicell market cap and key statistics
Omnicell’s market cap is $1.68B, with a P/E ratio of 41.5 and revenue of $1.25B over the last twelve months.
Valuation
- Market cap
- $1.68B
- P/E ratio
- 41.5
- Forward P/E
- 29.5
- EPS, TTM
- $0.84
- Gekko Fair Value
- $38.85
Trading
- Volume
- 459,029
- Avg volume, 20 days
- 511,752
- 52-week high
- $55.00
- 52-week low
- $29.06
- Shares outstanding
- 45.61M
Financials
- Revenue, TTM
- $1.25B
- Profit margin
- 3.1%
- Return on equity
- 3.1%
- Quarterly earnings growth, YoY
- +333.3%
Risk and income
- Beta
- 0.99
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±9.1%
Omnicell stock news this week
Coverage of Omnicell this week reads neutral: 0 positive, 4 neutral and 3 negative headlines.
- Financial Contrast: Baxter International (NYSE:BAX) and Omnicell (NASDAQ:OMCL)Defense World, Oct 11
- Learn Why The Bull Case For Omnicell Stock Could Change Following Weak EBITDA GuidanceSimply Wall Street, Oct 9
- Omnicell, Inc. (OMCL) stock price, news, quote and historyYahoo Finance Singapore, Oct 9
- Omnicell to release Q3FY26 results on October 29, 2026scanx.trade, Oct 9
- Press Release: Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026Moomoo, Oct 8
- Is Omnicell (OMCL) Undervalued As Weak EBITDA Guidance Clouds Its Earnings Beat?Simply Wall Street, Oct 8
Omnicell peers
Omnicell’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| IBMInternational Business Machines | Neutral | 12.9% below |
| FTNTFortinet | Neutral | 40.5% above |
| ACNAccenture | Neutral | 2.9% below |
| NETCloudflare | Neutral | 17.9% above |
| WDAYWorkday | Neutral | 11.7% above |
| CRDOCredo Technology | Neutral | 15.5% below |
A peer links to its own page where one exists.
Omnicell stock FAQ
What is Omnicell’s market cap?
Omnicell’s market cap is $1.68B at the Oct 12, 2026 close of $36.87, with 45.61M shares outstanding. The shares trade on a P/E ratio of 41.5.
What is the Omnicell stock forecast?
The consensus analyst 12-month price target for Omnicell is $57.86, +56.9% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Omnicell stock overvalued or undervalued?
On Gekko’s estimate Omnicell is undervalued: the Oct 12, 2026 close of $36.87 is 5.1% below Gekko Fair Value of $38.85. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Omnicell report earnings next?
Omnicell is expected to report on Oct 29, 2026, before the market opens (17 days away). Analysts expect earnings of $0.42 per share on revenue of $304.4M. Omnicell beat the earnings estimate in 7 of its last 8 reports, moving 14.2% on average across the report.
What is Omnicell’s 52-week high and low?
Omnicell’s 52-week high is $55.00 and its 52-week low is $29.06; it closed at $36.87 on Oct 12, 2026, +18.5% over the past year. Over the last five years the shares peaked at $187.29 on Nov 22, 2021.
Is Omnicell stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (fair value), 3 as mixed (trend, gekkoindex and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Omnicell the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.